SAM-e

S-Adenosylmethionine is a physiological molecule present in all tissues, most abundantly in the liver, and it functions as a cosubstrate in a wide range of enzyme reactions ^[4]. It is made inside cells from the essential amino acid methionine and adenosine triphosphate through the enzyme methionine adenosyltransferase, a reaction that gives the molecule a reactive sulfonium center ^[4]. That reactive center is what allows it to hand off a methyl group to other molecules, which is its central role in metabolism ^[1].

The compound sits at the crossroads of three major biochemical pathways. As the principal methyl donor it supplies the chemical tags added to DNA, RNA, proteins, and lipids in a process called transmethylation; through aminopropylation it contributes to the synthesis of polyamines; and through transsulfuration it feeds into the production of the antioxidant glutathione ^[1]. Because methylation touches so many processes, from gene regulation to the making of neurotransmitters, the level of S-adenosylmethionine is tightly controlled, and abnormal levels are linked to liver disease and other conditions ^[4].

As a supplement and medicine, S-adenosylmethionine has been examined most closely in three areas: depression, osteoarthritis, and liver disorders ^[1]. Reviews of clinical trials suggest it may have antidepressant effects, performing better than placebo in several studies and showing results broadly comparable to standard antidepressants, although the evidence is limited and the trials are often small ^[2][3]. Its role in liver health has been studied extensively in the laboratory, where keeping normal levels appears important for protecting the organ from injury ^[4]. Evidence for osteoarthritis and other proposed uses remains less conclusive ^[1].

Regulatory treatment of the compound varies by country. In the United States, Canada, and the United Kingdom it is available over the counter as a dietary supplement, becoming widely sold in the United States around the turn of the century, whereas in a number of European and other countries it is a prescription drug ^[1]. It is supplied in oral tablet form, usually enteric-coated to survive the stomach, and as an injectable preparation in some medical settings.

COMMON AND MILD, GASTROINTESTINAL. In the largest placebo-controlled trial, 19% reported stomach discomfort and 20% diarrhoea (PMID 24500245). Nausea and loose stools dominate adverse-event tables throughout the literature.

MANIA AND HYPOMANIA IS THE ONE SERIOUS SIGNAL. The Cochrane review counted 2 mania/hypomania events among 441 participants in SAM-e arms and told future trialists that induction of mania is of particular interest (PMID 27727432). NIH NCCIH advises that people with bipolar disorder should not take SAM-e for depressive symptoms except under clinician supervision, because it may worsen mania. A published case describes mania with psychotic features on SAM-e taken alongside an SSRI (PMID 29950497). A 2016 review states plainly that SAM-e is contraindicated in bipolar disorder (PMID 27594595).

SEROTONERGIC INTERACTION. One case of serotonin-syndrome-like symptoms occurred in the adjunctive trial (PMID 30115553), and NCCIH warns against combining SAM-e with drugs or supplements that raise serotonin. LEVODOPA: SAM-e may reduce its effect, since COMT methylates levodopa and SAM-e supplies the methyl group; relevant to anyone with Parkinson's disease.

HOMOCYSTEINE. A theoretical concern that chronic dosing raises homocysteine, and with it cardiovascular risk, is raised repeatedly (PMID 27594595) but was not borne out in the trial that actually measured it (PMID 30115553). Unresolved; folate and B12 status plausibly modify it.

PREGNANCY. Ademetionine is used clinically for intrahepatic cholestasis of pregnancy, but the 2020 Cochrane review of 26 trials and 2007 women concluded there is insufficient evidence that SAM-e is effective for it, with ursodeoxycholic acid the better-supported option (PMID 32716060). NCCIH states that safety in pregnancy has not been established. NCCIH also flags a theoretical concern for immunocompromised people including those who are HIV positive. Long-term safety data are limited.

REGULATORY. United States: dietary supplement under DSHEA, with no FDA approval for any indication and no requirement to prove efficacy. Italy, Germany and Russia: prescription drug, ademetionine, sold as Transmetil, Samyr, Heptral and Gumbaral, chiefly for intrahepatic cholestasis and chronic liver disease. ATC code A16AA02; ChEMBL CHEMBL1088977 at max clinical phase 3. Not a controlled or scheduled substance in any jurisdiction found. Not approved in the UK for depression.

WADA. SAM-e is not named on the Prohibited List and does not fall within any prohibited class (S0 to S9, P1, M1 to M3), so it should be permitted in and out of competition. Stated with a caveat: direct text search of the 2026 Prohibited List PDF could not be completed here (both fetches returned empty), and Global DRO does not index dietary supplements at all, so an athlete should confirm with their own anti-doping organisation. Ordinary supplement contamination risk applies regardless.

S-Adenosylmethionine was discovered in 1952 by the Italian-born biochemist Giulio Cantoni, working in the United States, who identified the elusive 'active methionine' and showed it to be the compound formed from methionine and ATP that serves as the cell's universal methyl donor. This finding established S-adenosylmethionine at the center of biological transmethylation and opened decades of research into its many roles. From the 1970s onward it was developed pharmaceutically, particularly in Europe, and studied for depression, osteoarthritis, and liver disease. It is sold as a prescription medicine in several countries, including Italy and Germany, and as an over-the-counter dietary supplement in the United States. Its metabolism is now understood to sit at the junction of transmethylation, transsulfuration toward glutathione, and polyamine synthesis.

SAM-e occupies an interesting middle ground between nutrient and medicine, being a molecule the body makes naturally that also shows genuine therapeutic promise. The accumulated evidence is encouraging for major depression, both as a stand-alone treatment and as an add-on to conventional antidepressants, and it has been studied with favorable results in osteoarthritis, where it has performed comparably to nonsteroidal anti-inflammatory drugs in some trials, as well as in certain liver conditions. Honesty requires noting that the trial literature, while promising, has limitations in size and consistency. Caution is also warranted in people with bipolar disorder, since its mood-elevating effect could in principle provoke a switch toward mania. On balance it is regarded as a well-tolerated option with a plausible biochemical rationale.